Benzinga · Mar 5, 2026
NASDAQ · TLRY
Tilray Brands, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$4.14
Down-$0.07 (-1.66%)
Updated Sep 11, 2026, 4:54 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 946.21M
- P/E ratio
- -0.3
- Dividend yield
- 0.00%
- 52-week range
- $3.67 – $9.34
- Volume
- 2.97M
- Avg. volume
- 7.17M
Price performance
TLRY price history
1M range · 20 trading sessions · Daily adjusted prices
TLRY closed at $4.14 after 20 trading sessions, down 11.91% for the selected period.
- Last close
- $4.14
- Period change
- -11.91%
- Period low
- $4.14
- Period high
- $4.88
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $4.17 | $4.26 | $4.10 | $4.14 | 2.97M |
| Sep 9, 2026 | $4.33 | $4.4155 | $4.18 | $4.21 | 4.95M |
| Sep 8, 2026 | $4.49 | $4.515 | $4.28 | $4.30 | 4.52M |
| Sep 4, 2026 | $4.51 | $4.54 | $4.45 | $4.50 | 2.76M |
| Sep 3, 2026 | $4.59 | $4.655 | $4.44 | $4.53 | 3.8M |
| Sep 2, 2026 | $4.47 | $4.67 | $4.46 | $4.52 | 3.22M |
| Sep 1, 2026 | $4.52 | $4.6801 | $4.48 | $4.50 | 3.49M |
| Aug 31, 2026 | $4.54 | $4.63 | $4.50 | $4.57 | 2.44M |
| Aug 28, 2026 | $4.55 | $4.655 | $4.49 | $4.59 | 3.38M |
| Aug 27, 2026 | $4.69 | $4.695 | $4.51 | $4.57 | 2.87M |
| Aug 26, 2026 | $4.84 | $4.86 | $4.60 | $4.64 | 4.16M |
| Aug 25, 2026 | $4.70 | $4.945 | $4.65 | $4.88 | 3.49M |
| Aug 24, 2026 | $4.80 | $4.80 | $4.61 | $4.72 | 3.1M |
| Aug 21, 2026 | $4.71 | $4.94 | $4.71 | $4.84 | 4.31M |
| Aug 20, 2026 | $4.76 | $4.81 | $4.55 | $4.67 | 3.76M |
| Aug 19, 2026 | $4.49 | $4.86 | $4.49 | $4.83 | 5.62M |
| Aug 18, 2026 | $4.42 | $4.58 | $4.38 | $4.47 | 2.79M |
| Aug 17, 2026 | $4.69 | $4.71 | $4.47 | $4.48 | 3.13M |
| Aug 14, 2026 | $4.70 | $4.71 | $4.52 | $4.67 | 3.27M |
| Aug 13, 2026 | $4.66 | $4.83 | $4.655 | $4.70 | 2.86M |
Latest TLRY news
The latest Smart Investors Daily articles mentioning TLRY.
Stock researchCompany · Overview
TLRY research
Overview
Company profile and research snapshot.
Company profile
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2026 | TD Cowen | Buy | — |
| Apr 2, 2026 | Roth Capital | Buy | — |
| Mar 30, 2026 | TD Cowen | Buy | — |
| Jan 20, 2026 | Roth Capital | Neutral | — |
| Aug 25, 2025 | Jefferies | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Mar 2, 2026
Tilray Brands, Inc. (TLRY) M&A Call Transcript
Benzinga · Mar 2, 2026
Tilray Brands Acquires BrewDog Assets — A $200 Million Revenue Boost On The Horizon
Tilray shares fall after closing $44 million BrewDog deal, targeting $1.2 billion annual revenue amid market weakness and stock pressure.
Benzinga · Mar 2, 2026
Trading Halt: Halt status updated at 10:40:00 AM ET: Quotation Resumption: News and Resumption Times
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
